SUMMARY Over 12 months serum was collected from 45 inpatients, with acute bronchopulmonary infection, in whose sputum Branhamella catarrhalis predominated, or was the sole pathogen. Serum was examined for IgG against B catarrhalis using an immunofluorescence antibody test. Acute and convalescent sera were compared with sera of age and sex matched controls. The convalescent sera had significantly higher titres than the acute sera which in turn had higher titres than the controls. The findings confirm the role of B catarrhalis as a respiratory pathogen and suggest that patients with chronic pulmonary disease are more prone to infection with this organism than the general population.
Over the past 10 years Branhamella catarrhalis has been increasingly recognised as an important pathogen, primarily of the respiratory tract. '2 Although initially thought to be solely an upper respiratory tract commensal, it has subsequently been associated with a wide variety of disease-acute otitis media in children,3 acute maxillary sinusitis, exacerbations of chronic obstructive airways disease (COAD)4-and less commonly with meningitis, endocarditis, conjunctivitis and bacteraemia.
Koch's postulates are as yet unfulfilled for B catarrhalis and definitive laboratory diagnosis must therefore depend largely on the serological response by the host to the invading pathogen. To date, serological data have been somewhat lacking concerning the role of this organism in pulmonary infection. Chapman et al, however, showed that most patients with pulmonary infections caused by B catarrhalis developed convalescent IgG antibody which had bactericidal activity, thought to be due to activation of the classical complement pathway.5
The purpose of this study was to determine the serological response of patients with Branhamella associated chest infections to Branhamella antigen and to compare them with an age and sex matched control group.
Accepted for publication 6 October 1987 Material and methods Over 12 months macroscopically purulent sputum samples from 45 inpatients aged 28-90 years were examined for the presence of B catarrhalis, using a liquefaction/dilutional technique. This method consisted of liquefying purulent sputum samples by diluting them 1/5 with buffered n-acetyl cysteine. The resultant solution was shaken for 15 minutes, and'then diluted to a final concentration of 1 in 5 x 105 with i strength Ringer's solution. A density of > I07 colony forming units/ml, occurring as the dominant or sole pathogen, was taken to be significant. The organism was confirmed to be B catarrhalis, by typical Gram stain, oxidase and catalase reactions, carbohydrate fermentation and nitrate reduction, in accordance with the criteria suggested by Doern and Morse. 6 The patients with positive sputum cultures were then interviewed, clinical details recorded, and the first serum sample taken. A second serum sample was taken as near to 10 days after the first, as was practicable before the patient's discharge, and the patient's progress was then recorded.
Serum As a final pretreatment, the cells were vortex mixed for two minutes to reduce autoagglutination and to promote an even distribution of cells. Aliquots (0-01 p1) of killed cell suspension were placed on a polytetrafluoroethylene coated multislide (HendleyEssex), which was then dried and fixed in acetone for 10 minutes. Test sera were diluted in a microtitre tray to give dilutions in the range 1/160 to 1/20480. These dilutions (0-01 p1 aliquots) were then placed on the prepared slides and incubated for 30 minutes at 37°C. The slides were then washed for 10 minutes in PBS before being dried. A 1/40 dilution of sheep derived, fluorescein labelled antihuman IgG (0-01 p1 aliquots) (Wellcome Diagnostics) was then placed on the slide and incubated for 30 minutes at 37°C. Treated slides were then mounted and viewed with the fluorescence microscope. Each pair of sera was prepared simultaneously, and each test carried out in triplicate, the final titre being a mean of the three readings. A positive control serum was obtained by rabbit inoculation with Branhamella antigen, derived from study strains numbers 1 to 10. A killed cell suspension was prepared as above. The cells were then washed six times in PBS before being resuspended in 0-5% formalin (in PBS) and diluted to a density of 108 cells/ ml. Antigen (0-1 ml) was inoculated intraperitoneally I IV/   1707  2133  2133  2133  2133  2133  2987  3413  5973   187  267  320  347  427  640  640  693   747  747  853  853  853  907  907  960  1067  1067  1173  1280  1280  1280  1280  1280  1387  1493  1707  1707  1707  1707  2133  2133  2560  2773  2987  2987  2987  2987  2987  2987  3627  4053  4267  6827  13653 at weekly intervals for four weeks. Serum samples were taken before inoculation and one week after the final dose of Branhamella antigen. These samples were tested for IgG against Branhamella by the above IFAT method but using sheep derived, fluorescein labelled antirabbit immunoglobulin (Wellcome Diagnostics) in the final stage. Anti-Branhamella IgG titres increased from 1/5 to 1/20480.
The positive control rabbit serum was used to determine the specificity of the IgG being tested, being absorbed in turn with pneumococcal, haemophilus, and staphylococcal antigens, before retesting with B catarrhalis antigen. This did not result in a lowering of titre against B catarrhalis. We therefore concluded that there was no significant cross reactivity between B catarrhalis and other possible respiratory pathogens. 187  267  320  347  427  640  640  693  747  747  853  853  853  907  907  960  1067  1067  1173  1280  1280  1280  1280  1280  1387  1493  1707  1707  1707  1707  2133  2133  2560  2773  2987  2987  2987  2987  2987  2987  3627  4053  4267  6827  13653   Convalescent sera   213  1173  427  373  427  853  853  5120  1387  2987  1707  1067  1067  853  1493  960  1280  1493  1920  1707  2133  1707  1493  1280  1493  1707  2560  8533  5120  2987  3413  3413  3413  2987  2987  2973  5333  4267  4693  5973  6827  4480  4267  7680  23893 Gaussian distribution and therefore a non-parametric statistical analysis was used (Wilcoxon's rank sum test). Using this method, the acute sera had higher titres of IgG against Branhamella than the control sera (p < 0O05). The convalescent sera had higher titres than both acute and control sera (p < 0-001).
Of the 45 patients in the study, 32 (71%) had a history of chronic pulmonary disease, and of these, 29 had COAD. Two patients with COAD had pulmonary carcinoma, two bronchiectasis, and a further five asthma, one of whom also had pulmonary carcinoma. One patient had pulmonary fibrosis associated with dust inhalation. In total, 30 patients (67%) were smokers. Fifteen patients (29%) also had extrapulmonary disease (table 1), or were receiving treatment which may have reduced their immunocompetence (table 2) . Discussion
Since its separation from the genus Neisseria, numerous studies have implicated Branhamella as a pathogen in man. 7 Ninane et aldescribed the organism as causing bronchopneumonia in coal miners.8 More recently, there have been reports of it causing chest infections in the immunocompromised and in premature infants. B catarrhalis has also been increasingly recognised as a relatively common isolate in both childhood otitis media and in exacerbations of COAD. The essential problem with Branhamella, however, is not in isolating the organism from sputum samples, but in determining its pathogenic potential. B catarrhalis has long been recognised as an upper airways commensal, and therefore its mere presence (unlike Mycobacterium tuberculosis) albeit in heavy, pure growth, is not an adequate criterion by which to gauge pathogenicity. Furthermore, sputum samples may become contaminated with oropharyngeal commensal organisms and may not therefore accurately reflect the lower respiratory tract flora. Thornley In this study, patients who were convalescent after an acute episode of pulmonary infection had a higher titre of IgG against Branhamella than matched controls, which was highly significant (p < 0-001). This would suggest recent immunological exposure to Branhamella antigen, and taken in conjunction with the clinical findings, would tend to confirm the ability of this organism to invade tissue and cause disease.
Black, Wilson
Of the 45 patients in the study, only four had a greater than four-fold rise in IgG titre, a further three having a two-fold or greater rise. This contrasts with the large statistical difference between the acute and convalescent groups when viewed as two entire populations. One possible explanation i&that the acute and convalescent sera were taken too close together. The mean time difference for the seven patients with the highest increase in titre was 14 days, compared with a mean of 10 days for the remainder of the group. It may be that the peak IgG titre occurred after the second sample was taken.
This study also showed high titres of IgG in the acute group compared with controls, although as mentioned above there was considerable overlap between the two groups especially at lower titres. The first serum samples were taken on average within two days of the patient developing purulent sputum which grew Branhamella. It seems unlikely that given this time span, a significant rise in titre had occurred. These titres may therefore reflect the "background" levels, and would suggest that the study population had greater immunological exposure to Branhamella than the control group. Patients with chronic bronchopulmonary disease may therefore be more prone to infection with Branhamella than the general population. Debilitated patients, or those with specifically compromised immune systems, also seem to be at greater risk of infection with B catarrhalis. As can be seen from table 1, an appreciable number of patients in the study had extrapulmonary disease, including two with myeloma, which could potentially adversely affect their immunocompetence. Similarly, as can be seen from table 2, a large number of patients in the study (33%) were receiving treatment that could also have affected their immune status. Furthermore, pulmonary infection was uncommon in those with no previous history of pulmonary or extrapulmonary disease. The association between B catarrhalis infection and impaired immune response has previously been described. Diamond et al reported four cases of B catarrhalis pneumonia in patients with abnormalities of their humoral immune system, including one patient with multiple myeloma." He concluded that normal immunoglobulins are an important host defence mechanism in protecting against infection with this pathogen. It is also worth noting that the first reported case ofB catarrhalis pneumonia in the United States was in a patient with myeloma.'2 The patient subsequently died from fulminating pneumonia. The prognosis of Branhamella pneumonia in cases of myeloma is especially poor.
In conclusion, while bronchopulmonary infection from this organism is not as prevalent in Northern Ireland as in some other countries,'3 it is nevertheless an important respiratory pathogen, especially when isolated from patients with COAD, or in the immuncompromised. This may have implications for treatment, ;. in this study 41 (91%) strains were ,B lactamase producers and were generally resistant to the commonly used oral penicillins (unpublished data).
